Patient Voice/Patient-Focused Drug Development
Patient involvement is increasingly being recognized as important to successful research and development of medicines and care. Patient-focused drug development (PFDD) is an emerging set of practices for engagement with patients and generating data on patients’ and caregivers’ experiences.
This Working Group will consider current guidance and practices to identify needed tools and resources to further promote and embed the patient voice from molecule to market.
Group Leaders: Neil Bertelsen, Dave Bjork
Neil Bertelsen
HTAi Patient and Citizen Involvement Group
Neil has over 25 years’ experience in bringing the patient voice to life for healthcare decision makers. Neil has been a patient advocate, and is the past chair of HTAi’s patient & citizen involvement group where he continues to work with HTA bodies around the world on improvements to patient engagement in HTA...
View Bio
Neil Bertelsen
HTAi Patient and Citizen Involvement Group
Neil has over 25 years’ experience in bringing the patient voice to life for healthcare decision makers. Neil has been a patient advocate, and is the past chair of HTAi’s patient & citizen involvement group where he continues to work with HTA bodies around the world on improvements to patient engagement in HTA. Neil is also a board member of Patient Focused Medicines Development, an international multi-stakeholder effort to bring patients into the heart of medicine research and development. Neil regularly works with patient groups, healthcare decision-makers and the industry to collectively develop approaches that benefit patients.